Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 3/20 | 0.58 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.58 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.54 |
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 9/20 | 0.44 |
| ▸ | LOX | P28300 | 3/20 | 0.44 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.44 |
| ▸ | FERMT2 | Q96AC1 | 2/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15219374 | 0.80 | ROCK1 (0.49) | ROCK1LOXL2LOXLOXL3NOS1 | |
| SCHEMBL5519979 | 0.80 | LOXL2 (0.52) | NR4A2SOS2ROCK1LOXL2LOX | |
| SCHEMBL23420994 | 0.80 | NR4A2 (0.51) | NR4A2SOS2ROCK1NCF1 | |
| SCHEMBL12146616 | 0.79 | ROCK1 (0.47) | NR4A2SOS2ROCK1LOXL2LOX | |
| SCHEMBL3073397 | 0.76 | NR4A2 (0.66) | NR4A2SOS2NCF1 | |
| SCHEMBL30044428 | 0.76 | NR4A2 (0.66) | NR4A2SOS2NCF1 | |
| SCHEMBL11916090 | 0.76 | ROCK1 (0.45) | NR4A2SOS2ROCK1LOXL2LOX | |
| SCHEMBL3964351 | 0.74 | ROCK1 (0.54) | ROCK1 | |
| SCHEMBL2860410 | 0.74 | LOXL2 (0.47) | ROCK1LOXL2LOXLOXL3NOS1 | |
| SCHEMBL31367022 | 0.74 | LOXL2 (0.47) | ROCK1LOXL2LOXLOXL3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166589-B2 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20060148794-A1 | Neuropeptide Y antagonist; antiarthritic agents; cardiovascular disorders; antidiabetic agents; kidney disorders; eating disorders; obesity | KLUG MICHAEL G | 2006-07-06 | — | — | US | disclosed |
| US-7064134-B2 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-06-20 | — | — | US | disclosed |
| US-20060063758-A1 | Neuropeptide Y antagonist; antiarthritc agents; cardiovascular disorders; antidiabetic agents; kidney diseases; eating disorders; obesity | KLUG MICHAEL G | 2006-03-23 | — | — | US | disclosed |
| US-7012073-B2 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-03-14 | — | — | US | disclosed |
| US-20040259858-A1 | Quinoline derivatives | KLUG MICHAEL G (US) | 2004-12-23 | — | — | US | disclosed |
| US-6787558-B2 | NEUROPEPTIDE Y RECEPTOR ANTAGONISTS, FOR TREATING ARTHRITIS, CARDIOVASCULAR DISEASES, DIABETES, RENAL FAILURE, EATING DISORDERS AND OBESITY | HOFFMANN-LA ROCHE INC. | 2004-09-07 | — | — | US | disclosed |
| EP-1432421-A1 | QUINOLINE DERIVATIVES AS NEUROPEPTIDE Y ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2004-06-30 | — | — | EP | disclosed |
| US-20030158179-A1 | Quinoline derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2003-08-21 | — | — | US | disclosed |
| WO-2003028726-A1 | QUINOLINE DERIVATIVES AS NEUROPEPTIDE Y ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158179-A1 | Quinoline derivatives | RAB1A, GLS, REN | NR4A2 1189/4885SOS2 4528/4885ROCK1 1048/4885 |
| US-20060148794-A1 | Neuropeptide Y antagonist; antiarthritic agents; cardiovascular disorders; antidiabetic agents; kidney disorders; eating disorders; obesity | NPY1R, NPY2R, NPY4R | NR4A2 1010/4885SOS2 4683/4885ROCK1 1599/4885 |
| US-20040259858-A1 | Quinoline derivatives | RAB1A, GLS, REN | NR4A2 1189/4885SOS2 4528/4885ROCK1 1048/4885 |
| US-20060063758-A1 | Neuropeptide Y antagonist; antiarthritc agents; cardiovascular disorders; antidiabetic agents; kidney diseases; eating disorders; obesity | NPY1R, NPY2R, NPY4R | NR4A2 1356/4885SOS2 4825/4885ROCK1 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.